Skip to content

Author

J. Ahn

We have 2 of 115 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Molecular and immune heterogeneity across limited-stage and extensive-stage small cell lung cancer.

Immune checkpoint inhibitors are now standard care for small-cell lung cancer (SCLC); however, a profound prognostic disparity persists between limited-stage (LS) and extensive-stage (ES) disease. Although clinical staging defines tumor spread, the specific molecular characteristics distinguishing LS from ES remain poo...

Jiyeon Kim, Kyoung Lee, Hyemin Kim et al. · 0 citations
Open access Oct 2026

Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.

BACKGROUND Therapeutic strategies after progression on third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) remain suboptimal in EGFR-mutant non-small cell lung cancer (NSCLC). We investigated whether continuing EGFR inhibition with lazertinib combined with platinum-pemetrexed chemotherapy could extend clinical...

M. Hong, B. Shim, C. Kim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.